Trung Huynh
Stock Analyst at UBS
(3.34)
# 844
Out of 4,814 analysts
37
Total ratings
51.85%
Success rate
15.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $49.23 | +9.70% | 5 | Apr 11, 2025 | |
| PFE Pfizer | Maintains: Neutral | $28 → $24 | $22.15 | +8.38% | 5 | Apr 8, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $1.11 | +530.63% | 2 | Apr 1, 2025 | |
| INSM Insmed | Maintains: Buy | $105 → $110 | $72.47 | +51.79% | 4 | Mar 6, 2025 | |
| JSPR Jasper Therapeutics | Initiates: Buy | $38 | $3.97 | +857.18% | 1 | Feb 13, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Buy | $44 | $18.29 | +140.57% | 1 | Feb 13, 2025 | |
| REGN Regeneron Pharmaceuticals | Downgrades: Neutral | $1,130 → $738 | $563.16 | +31.05% | 1 | Jan 16, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $1.85 | +604.61% | 1 | Oct 10, 2024 | |
| LLY Eli Lilly and Company | Assumes: Buy | $612 → $710 | $839.90 | -15.47% | 7 | Oct 20, 2023 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $170 → $175 | $157.44 | +11.15% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $220 → $200 | $277.29 | -27.87% | 3 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $77.98 | +61.58% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $173.00 | -1.73% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $7.07 | - | 1 | Mar 23, 2021 |
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $49.23
Upside: +9.70%
Pfizer
Apr 8, 2025
Maintains: Neutral
Price Target: $28 → $24
Current: $22.15
Upside: +8.38%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.11
Upside: +530.63%
Insmed
Mar 6, 2025
Maintains: Buy
Price Target: $105 → $110
Current: $72.47
Upside: +51.79%
Jasper Therapeutics
Feb 13, 2025
Initiates: Buy
Price Target: $38
Current: $3.97
Upside: +857.18%
Celldex Therapeutics
Feb 13, 2025
Initiates: Buy
Price Target: $44
Current: $18.29
Upside: +140.57%
Regeneron Pharmaceuticals
Jan 16, 2025
Downgrades: Neutral
Price Target: $1,130 → $738
Current: $563.16
Upside: +31.05%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $1.85
Upside: +604.61%
Eli Lilly and Company
Oct 20, 2023
Assumes: Buy
Price Target: $612 → $710
Current: $839.90
Upside: -15.47%
Johnson & Johnson
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $157.44
Upside: +11.15%
Jul 12, 2023
Maintains: Outperform
Price Target: $220 → $200
Current: $277.29
Upside: -27.87%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $77.98
Upside: +61.58%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $173.00
Upside: -1.73%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $7.07
Upside: -